Cytek Biosciences Reports First Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Cytek Biosciences, Inc. (CTKB) Misses Q1 EPS by 7c, Misses on Revenue; Offers FY25 Revenue Guidance
May 8, 2025 4:36 PM EDTCytek Biosciences, Inc. (NASDAQ: CTKB) reported Q1 EPS of ($0.09), $0.07 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $43.82 million.
GUIDANCE:
Cytek Biosciences, Inc. sees FY2025 revenue of $196-210 million, versus the... More
